Amgen China R&D Head Mingqiang Zhang On R&D Inroads In China
This article was originally published in The Pink Sheet Daily
Executive Summary
In a conversation at the sidelines of the PharmAsia Summit Shanghai, Zhang talks about Amgen R&D strategy in China, which includes partnering with local research institutions, accelerating introduction of its portfolio in China and beefing up its local discovery capability.